Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Kausik Ray Articles

An update on inclisiran

An update on inclisiran

Reports from the 7th Expert Meeting of PCSK9 Forum Kausik Ray

read more »
ESC Congress 2017: CANTOS shows it’s not all about lipids

ESC Congress 2017: CANTOS shows it’s not all about lipids

The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) study (1) showed that treatment with canakinumab, an inhibitor of interleukin-1β (IL-1β), reduced the risk of major adverse cardiovascular events. Lead author, Professor Paul Ridker (Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, Boston, USA) compared…

read more »
PlayProf Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Watch out PCSK9 monoclonal antibodies: inclisiran (formerly known as PCSK9si and ALN-PCSsc) has made its mark at ACC.2017. Results of the phase 2 ORION-1 trial in patients with elevated LDL cholesterol despite maximally tolerated statin therapy, showed that 2 single injections of inclisiran 300 mg…

read more »
A global call to arms for FH­

A global call to arms for FH­

Over 40 experts from around the world have joined forces to for urgent action on familial hypercholesterolaemia. The European Atherosclerosis Society (EAS) FH Studies Collaboration (FHSC), led by Professor Kausik Ray, Imperial College London, UK, aims to address a number of challenges in FH. There…

read more »
PlayACC/AHA guidelines: Where do the new treatments fit?

ACC/AHA guidelines: Where do the new treatments fit?

Professor Kausik Ray reports on ACC AHA guidelines and where new treatments fit.

read more »
PlayResidual cardiovascular risk – a role for PCSK9 inhibition

Residual cardiovascular risk – a role for PCSK9 inhibition

Many people treated with statins and other cholesterol lowering drugs have a modifiable residual risk of cardiovascular disease because their low density lipoprotein cholesterol (LDL-C) is still too high. Professor Kausik Ray says there is an unmet need for improved treatments in patients who cannot…

read more »